Video Insights

Top 3 Liver-Directed Therapies for Colorectal Cancer Metastases
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Advertisement
Christopher Lieu, MDColorectal Cancer | May 16, 2025
Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.
Samuel Cytryn, MDGastric Cancer | May 9, 2025
Dr. Cytryn considers two studies evaluating PD-1 inhibition in patients with MSI-high tumors in the locally advanced setting.
Jeanne Tie, MD, MBChBColorectal Cancer | May 1, 2025
Dr. Tie discusses the beneficial results seen with a ctDNA-guided approach, and touches on its role in future trials.
Yelena Janjigian, MDGastric Cancer | April 15, 2025
Dr. Janjigian reviews KEYNOTE-811, and how it led to the FDA approval of pembrolizumab for HER2-positive gastric cancers.
Stephen Liu, MDPancreatic Cancer | April 15, 2025
Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.
Stephen Liu, MDPancreatic Cancer | April 15, 2025
Drs. Stephen Liu and Benjamin Weinberg elaborate on the prevalence of NRG1 gene fusions in PDAC.
Michael Foote, MDColorectal Cancer | April 7, 2025
Low-dose aspirin halved recurrence in resected PIK3CA-mutated colorectal cancer, per data from the ALASCCA trial.
Michael Foote, MDColorectal Cancer | April 4, 2025
Dr. Michael Foote breaks down the CheckMate 8HW trial and supports dual immunotherapy as a first-line option in dMMR CRC.
Michael Foote, MDColorectal Cancer | April 1, 2025
Dr. Foote discusses the BREAKWATER trial and the impact of BRAF-targeted therapy in metastatic colorectal cancer.
Richard Kim, MDBile Duct Cancer | March 22, 2025
Dr. Kim discusses how ctDNA compares to traditional imaging and how findings can affect adjuvant treatment decisions for BTC.
Cathy Eng, MD, FACP, FASCOColorectal Cancer | March 21, 2025
Dr. Eng discusses the rising global incidence of early-onset CRC, as highlighted in a recent Lancet Oncology publication.
Samuel Cytryn, MDGastric Cancer | March 19, 2025
Dr. Cytryn shares insights on the implications of recent data from the DESTINY-Gastric04 and MATTERHORN trials.
Laurence Albiges, MD, PhDGastric Cancer | March 19, 2025
Dr. Albiges shares her thoughts on the FDA approval of subcutaneous nivo in gastric cancer and how it will impact practice.
Elizabeth Auckley, MDPancreatic Cancer | February 14, 2025
Challenges in designing and conducting clinical trials for patients with metastatic pancreatic ductal cancer are discussed.
Elizabeth Auckley, MDPancreatic Cancer | February 14, 2025
The efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies.
Elizabeth Auckley, MDPancreatic Cancer | February 14, 2025
The KRAS G12R mutation is analyzed against other alterations in pancreatic adenocarcinoma, and research findings are shared.
Samuel Cytryn, MDGastric Cancer | March 19, 2025
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
Richard S. Finn, MDLiver Cancer | February 7, 2025
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
Advertisement